Polyrizon
Polyrizon is a biotech company focused on developing and commercializing innovative intranasal products. Their platform technologies include Capture & Contain™ (C&C) and Trap & Target™ (T&T), which aim to protect the human body from airborne threats like allergens, viruses, and molds, and improve drug delivery through the nasal cavity. The company is engaged in research and development of products to prevent and treat respiratory illnesses, allergies, and viral infections, including COVID-19, with a mission to protect patients differently and expand horizons of intranasal care.
Industries
Nr. of Employees
small (1-50)
Polyrizon
Products
Capture and Contain
A proprietary mucoadhesive nasal hydrogel platform based on a natural 3-D polymeric network designed to adhere to the nasal mucosal surface, creating a physical barrier that captures and contains airborne biological assaults like allergens, viruses, and molds.
Trap & Target
A tunable intranasal drug delivery technology platform designed to allow a long residence time and intimate contact with mucosal tissue for targeted delivery of medicines.
Capture and Contain
A proprietary mucoadhesive nasal hydrogel platform based on a natural 3-D polymeric network designed to adhere to the nasal mucosal surface, creating a physical barrier that captures and contains airborne biological assaults like allergens, viruses, and molds.
Trap & Target
A tunable intranasal drug delivery technology platform designed to allow a long residence time and intimate contact with mucosal tissue for targeted delivery of medicines.
Expertise Areas
- Intranasal drug delivery
- Mucoadhesive biomaterials and hydrogels
- Controlled-release nasal formulations
- Preclinical antiviral and anti-allergy testing
Key Technologies
- Mucoadhesive polymer networks
- Hydrogel barrier systems
- Biodegradable polymers
- Controlled-release formulation technologies